COVID-19 Impact

You may see some delays in posting new content due to COVID-19. If you have any questions, please submit a message to PSNet Support.
 

PSNet: Patient Safety Network
Press Release/Announcement

FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration. July 23, 2020.

Accidental misuse of prescription opiates for pain can result in addiction, overdose and death. This announcement outlines new federal labeling requirements for opiates and treatments for opioid use disorder. The FDA calls for health care professionals to educate patients about naloxone when prescribing opioid medications to improve the safety of patients taking opiates.